Pfizer Pneumococcal Vaccine Approved in Malaysia
Broader Protection for Malaysian Children: Introducing PCV20 for Enhanced Pneumococcal Defence
Table of Contents
Malaysia is poised to strengthen its defence against pneumococcal disease with the introduction of PCV20, a new vaccine offering broader serotype coverage. This advancement addresses the dynamic nature of circulating pneumococcal serotypes and aims to provide enhanced protection for Malaysian children against serious infections like pneumococcal meningitis and sepsis.
Addressing Evolving Pneumococcal Serotypes
Pneumococcal disease, caused by Streptococcus pneumoniae, remains a significant public health concern, especially for young children whose immune systems are still developing. While existing vaccines have been instrumental in reducing the burden of the disease, the emergence of new serotypes necessitates updated vaccination strategies.
“Every parent wants to give their child the best start in life, and as paediatricians, we see just how significant the early years are in shaping lifelong health,” said Prof Dr Zulkifli Ismail, a consultant paediatrician and paediatric cardiologist.”A child’s immune system is still developing in those first few years, and this is when they are most vulnerable to serious infections like pneumococcal meningitis or sepsis, which can have lasting consequences.”
PCV20 has been developed to address this gap, offering broader serotype coverage in response to emerging disease patterns. This evolution in vaccine technology is crucial for staying ahead of the pathogens that cause pneumococcal infections.
Built on Pfizer’s Legacy: PCV7 → PCV13 → PCV20
Pfizer has a long-standing commitment to combating pneumococcal disease, with a history of developing increasingly comprehensive vaccines. The company introduced its first pneumococcal conjugate vaccine, the 7-valent pneumococcal conjugate vaccine (PCV7), over two decades ago. This was followed by the 13-valent pneumococcal conjugate vaccine, PCV13.
Thes vaccines have been widely adopted globally and are integral components of public immunisation programmes. PCV20 represents the next significant evolution, meticulously designed to reflect current disease patterns and evolving population needs.
“In recent years, we have observed the rise of non-PCV13 serotypes globally. Serotype 8 has emerged as a leading cause of invasive pneumococcal disease in both children and adults, a trend that has persisted in recent years,” stated Prof dr Mark van der Linden, director, National Reference Center for Streptococci in Germany. “The shift in epidemiology reinforces the importance of higher-valent vaccines like PCV20,which close critical gaps in protection and reflect the latest scientific understanding.”
Strengthening Malaysia’s Immunisation Landscape
The introduction of PCV20 is also seen as a vital step in strengthening malaysia’s broader immunisation landscape, including for adults. Public education and consistent disease awareness campaigns are highlighted as key strategies for successful implementation.
“As we work to strengthen Malaysia’s adult immunisation landscape, public education and consistent disease awareness campaigns will be key,” said Prof Dr Zamberi Sekawi, president of the Malaysian Society of Infectious Diseases and Chemotherapy. “Now that PCV20 is available, we must mobilise to strengthen adult immunisation in Malaysia. Healthcare professionals are key messengers in encouraging more adults to get immunised. With support from medical societies, policymakers, and the media, we can build a healthier, better-protected nation.”
PCV20 has already received approval in over 40 countries, including major health markets such as the United States, the United kingdom, Hong Kong, and Singapore. its approval in Malaysia is underpinned by comprehensive data from extensive adult and paediatric clinical studies. these studies have demonstrated comparable immune responses to PCV13 for the original 13 serotypes, alongside robust additional immunogenicity for the seven newly included strains. Furthermore,the vaccine has shown consistent tolerability across various age groups,even when administered concurrently with other routine vaccinations,underscoring its safety profile.